- Record: found
- Abstract: not found
- Article: not found
Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data
W. Joseph Herring ,
Kathryn M. Connor ,
Ellen Snyder ,
Duane B. Snavely ,
Charles M. Morin ,
Christopher Lines ,
David Michelson
October 2018
October 2018
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d1233392e115">Suvorexant is an orexin receptor antagonist that
is approved in the US, Japan and
Australia for the treatment of insomnia. Using outcomes from the Insomnia Severity
Index (ISI) in the core registration studies, we explored suvorexant effects on sleep
problems and their impact on daytime function.
</p>